Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
Badreddin Edris(Stanford Medicine), Matt van de Rijn(Stanford University), Kipp Weiskopf(California Institute for Regenerative Medicine), Robert B. West(Stanford University), Humberto Contreras-Trujillo(California Institute for Regenerative Medicine), Ravindra Majeti(Stanford University), Irving L. Weissman(California Institute for Regenerative Medicine), Jie Liu(Children's Hospital of Chongqing Medical University), Andrew H. Beck(Brown University), Jonathan A. Fletcher(Harvard University), Jens-Peter Volkmer(Menlo School), Anne Kathrin Volkmer(California Institute for Regenerative Medicine), Stephen B. Willingham(Silvus Technologies (United States))
Cited by 256
Related Papers
Stem cells, cancer, and cancer stem cells
|Nature|2001|9.7k
Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer
|JAMA|2017|3.3k
Epigenetic memory in induced pluripotent stem cells
|Nature|2010|2.3k
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
|Nature|2017|2.3k
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
|Proceedings of the National Academy of Sciences|2012|1.6k